首页 /
/ iRGD抗肿瘤靶向药物输送系统/iRGD tumor penetrating peptide technology for drug delivery
iRGD抗肿瘤靶向药物输送系统/iRGD tumor penetrating peptide technology for drug delivery
本靶向药物输送系统可以提高抗肿瘤药物疗效、降低毒副作用。已于2018年8月开始在澳大利亚进行针对转移性胰腺癌的一期临床试验。
●特异靶向实体瘤新生血管
●引导药物穿透血管壁进入实体瘤内部（至少3mm）
●物理混合即可生效：无需化学修饰或包装药物载荷
This tumor penetrating peptide technology The targeted drug delivery system can improve the efficacy of anti-tumor drugs and reduce toxicity and other side decrease toxic and side effect. Phase I clinical trial was initiated in August 2018 in Australia for patients with metastatic pancreatic ductal adenocarcinoma.
●Target tumor angiogenesis with high specificity
●Active transport drugs through blood vessels into solid tumor (deeper than 3mm)
●Bystander effect: no covalent modification or encapsulation needed for payloads
